A cell-based medicine for repairing knee damage has become the first product to be recommended for approval by the European Medicines Agency under the European Union’s new advanced therapy regulatory framework 1.
ChondroCelect, which is produced by the Belgian biomedical company TiGenix, is used to repair defects in the cartilage of the femoral condyle (the end of the thighbone) in the knee...
Please Login to read the full article.
